Katherine Stueland, serving as the Chief Executive Officer of GeneDx Holdings Corp. (NASDAQ:WGS), executed a series of equity divestitures totaling approximately $638,104 on June 16, 2026. According to filings submitted to the Securities and Exchange Commission, the transaction involved the sale of 10,501 shares of the company’s Class A Common Stock. The execution of these sales occurred at weighted average prices ranging from $59.7543 to $61.5035 per share. Individual transaction clusters were recorded within specific price bands: $59.26 to $60.24, $60.40 to $61.35, and $61.44 to $61.69.
The current trading price of WGS stands at $59.01, a valuation level that reflects a challenging six-month period for the equity, during which shares have declined by 58.6%. Analysis provided by InvestingPro, which monitors over 1,400 US equities with comprehensive research reports, suggests that WGS appears overvalued relative to its calculated Fair Value of $53.17. The recent sales were not discretionary moves by Ms. Stueland but were undertaken specifically to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units. These transactions are formally categorized as 'sell to cover' events.
Prior to the execution of these sales, Ms. Stueland acquired 18,750 shares of Class A Common Stock through the vesting of RSUs, receiving these shares for no consideration. Each RSU represents a contingent right to receive one share of the Issuer’s Class A Common Stock upon settlement. The vesting schedule operates on a quarterly basis, with the first tranche having vested on June 16, 2023, contingent upon Ms. Stueland’s continued service to the company.
Following the reported transactions, Ms. Stueland’s direct holdings in GeneDx Holdings Corp. Class A Common Stock total 104,372 shares. Additionally, she retains RSUs representing contingent rights to receive up to an aggregate of 305,525 shares and holds options to purchase up to an aggregate of 107,610 shares, both of which vest according to their respective terms.
The executive transaction coincides with significant operational and financial developments at GeneDx. The company recently reported its first-quarter 2026 earnings, which fell short of market expectations. GeneDx announced an EPS of -$0.28, missing the forecast of -$0.01, and reported revenue of $102.3 million, which was below the anticipated $112.45 million.
In response to the earnings report, Canaccord reduced its price target for GeneDx from $100 to $75. The firm cited a more muted revenue outlook due to lower average selling prices and test volume expansion. Similarly, BTIG cut its price target for GeneDx from $170 to $90, maintaining a Buy rating but noting the company’s reduced 2026 revenue and volume guidance. The revised revenue outlook was attributed to a higher mix of genome tests, with genome reimbursement still in early stages compared to exome tests.
In addition to these financial developments, GeneDx appointed Mark Gardner as president, focusing on strengthening execution and scaling operations. Meanwhile, TD Cowen reported shifts in short interest among life science tools and diagnostics stocks, although specific impacts on GeneDx were not detailed. These developments highlight the company’s ongoing strategic adjustments and market challenges.